拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

盘后交易 05-07 16:55:21 EDT

82.58

+0.48

+0.58%

盘后82.58

+0.000.00%

16:39 EDT

最高83.02	最低81.77	成交量90.48万
今开82.40	昨收82.10	日振幅1.52%
总市值156.80亿	流通市值155.60亿	总股本1.90亿
成交额7,474万	换手率0.48%	流通股本1.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":82.58,"timestamp":1715112000000,"preClose":82.1,"halted":0,"volume":904833,"hourTrading":{"tag":"盘后","latestPrice":82.58,"preClose":82.58,"latestTime":"16:39 EDT","volume":44207,"amount":3650620.24898,"timestamp":1715114345629},"delay":0,"floatShares":188422247,"shares":189879803,"eps":1.070064,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.48,"latestTime":"05-07 16:55:21 EDT","open":82.4,"high":83.02,"low":81.77,"amount":74739260.08998,"amplitude":0.015225,"askPrice":84.17,"askSize":20,"bidPrice":80.99,"bidSize":20,"shortable":3,"etf":0,"ttmEps":1.070064,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715126400000},"adr":0,"listingDate":932702400000,"adjPreClose":82.1,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":82.52,"preClose":82.1,"latestTime":"09:29 EDT","volume":380,"amount":31358.607,"timestamp":1715088599999},"postHourTrading":{"tag":"盘后","latestPrice":82.58,"preClose":82.58,"latestTime":"16:39 EDT","volume":44207,"amount":3650620.24898,"timestamp":1715114345629},"volumeRatio":0.59143},"requestUrl":"/m/hq/s/BMRN/tweets","defaultTab":"tweets","newsList":[{"id":"2430399282","title":"拜玛林制药2024财年第一财季实现净利润88.66百万美元，同比增加74.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430399282","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430399282?lang=zh_cn&edition=full","pubTime":"2024-04-26 00:19","pubTimestamp":1714061959,"startTime":"0","endTime":"0","summary":"3月31日，拜玛林制药公布财报，公告显示公司2024财年第一财季净利润为88.66百万美元，同比增加74.36%；其中营业收入为6.49亿美元，同比增加9.44%，每股基本收益为0.47美元。从资产负债表来看，拜玛林制药总负债17.99亿美元，其中短期债务4.94亿美元，资产负债比为3.83，流动比率为2.75。机构评级：截至2024年3月31日，当前有25家机构对拜玛林制药目标价做出预测，其中目标均价为110.23美元，其中最低目标价为80.00美元，最高目标价为140.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260019258b53b3bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260019258b53b3bb&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430280307","title":"BUZZ-BioMarin 在第一季度收入不及预期后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2430280307","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430280307?lang=zh_cn&edition=full","pubTime":"2024-04-25 23:03","pubTimestamp":1714057381,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月25日 - ** 制药公司 BioMarin Pharmaceutical    股价下跌 ~10.8% 至 81.35 美元** 周三收盘后，该公司公布的 (link) 第一季度营收为 6.488 亿美元，低于分析师平均预期的 6.518 亿美元 - LSEG 数据** BMRN 季度利润为每小时 71 美分，分析师平均预期为每小时 34 美分。** 包括本交易日的走势在内，该股今年累计下跌约 15.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430285852","title":"拜玛林制药盘中异动 大幅跳水6.36%报85.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430285852","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430285852?lang=zh_cn&edition=full","pubTime":"2024-04-25 21:32","pubTimestamp":1714051944,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日21时32分，拜玛林制药股票出现波动，股价快速下跌6.36%。截至发稿，该股报85.40美元/股，成交量41.73万股，换手率0.22%，振幅4.14%。最近的财报数据显示，该股实现营业收入24.19亿美元，净利润1.68亿美元，每股收益0.89美元，毛利18.42亿美元，市盈率98.16倍。拜玛林制药股票所在的生物技术行业中，整体跌幅为0.50%。拜玛林制药公司简介：BioMarin的重点是罕见疾病的治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042521322487af68cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042521322487af68cd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429014509","title":"Biomarin Pharmaceutical Inc   预计每股收益35美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2429014509","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2429014509?lang=zh_cn&edition=full","pubTime":"2024-04-23 05:20","pubTimestamp":1713820811,"startTime":"0","endTime":"0","summary":"   * Biomarin Pharmaceutical Inc    将于4月24日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* 根据LSEG的数据，22位分析师的平均预期显示，这家总部位于加利福尼亚州诺瓦托的公司的营收将从去年同期的5.9642亿美元增长9.3%，达到6.51788亿美元。* LSEG 分析师对 Biomarin Pharmaceutical Inc 的平均预期为每股收益 35 美分。* 华尔街对 Biomarin Pharmaceutical Inc 的 12 个月目标价中位数为 110.00 美元，高于其最新收盘价 88.63 美元。4月22日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422535118","title":"维升药业三冲港交所IPO：增高针数据不及竞品前景待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2422535118","media":"华尔街见闻","top":-1,"share":"https://www.laohu8.com/m/news/2422535118?lang=zh_cn&edition=full","pubTime":"2024-03-25 09:50","pubTimestamp":1711331414,"startTime":"0","endTime":"0","summary":"失之毫厘，差之千里？","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/content_default_5.jpg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/content_default_5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3711208","is_publish_highlight":false,"gpt_icon":0},{"id":"2414851810","title":"更新版 1-BioMarin Pharma 收到司法部传票，内容涉及两种疗法的赞助测试计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2414851810","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414851810?lang=zh_cn&edition=full","pubTime":"2024-02-27 03:36","pubTimestamp":1708976194,"startTime":"0","endTime":"0","summary":"     路透社2月26日 - BioMarin Pharmaceutical   在周一提交的一份文件中称， 已收到美国司法部的传票，要求提供该公司赞助的与两种治疗方法有关的测试项目的信息。BioMarin表示，司法部要求该公司提交与赞助测试其疗法Vimizim和Naglazyme有关的某些文件。Vimizim 是一种酶替代疗法，已被批准用于治疗 Morquio A 综合征，这是一种影响主要器官系统的罕见遗传性疾病。BioMarin 的另一种疗法 Naglazyme 获准用于治疗一种遗传性疾病--粘多糖病 VI。司法部没有立即回应路透社的置评请求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413273894","title":"美国研究综述-Biomarin Pharmaceutical、Intuit、Penumbra","url":"https://stock-news.laohu8.com/highlight/detail?id=2413273894","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413273894?lang=zh_cn&edition=full","pubTime":"2024-02-23 15:28","pubTimestamp":1708673314,"startTime":"0","endTime":"0","summary":"    路透社2月23日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Biomarin Pharmaceutical、Intuit 和 Penumbra。要闻             * Biomarin Pharmaceutical Inc   ：Piper Sandler将目标价从115美元下调至107美元             * Intuit Inc   ：Susquehanna将目标价从700美元上调至775美元             * Penumbra Inc   ：摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413204955","title":"Biomarin Pharmaceutical Inc 公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2413204955","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413204955?lang=zh_cn&edition=full","pubTime":"2024-02-23 11:15","pubTimestamp":1708658158,"startTime":"0","endTime":"0","summary":"   * Biomarin Pharmaceutical Inc   公布的截至12月底的季度调整后每股收益为18美分，高于去年同期的每股盈亏平衡收益。25 位分析师对该季度的平均预期是每股收益 23 美分。华尔街预期为每股收益 11 美分至 39 美分。* Biomarin Pharmaceutical Inc公布的本季度每股收益为11美分。* 该公司报告的季度净收入为2038万美元。* Biomarin Pharmaceutical Inc 本季度股价下跌了 8.2%。华尔街对 Biomarin Pharmaceutical Inc 的 12 个月目标价中位数为 109.95 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2406720792","title":"美国研究综述-Amerant Bancorp、陶氏、Humana","url":"https://stock-news.laohu8.com/highlight/detail?id=2406720792","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2406720792?lang=zh_cn&edition=full","pubTime":"2024-01-26 23:45","pubTimestamp":1706283921,"startTime":"0","endTime":"0","summary":"    路透1月26日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价，其中包括 Amerant Bancorp、陶氏和 Humana。要闻 * Amerant Bancorp Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2393110452","title":"BioMarin 与 Elliott 达成和解，增加 3 名独立董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2393110452","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2393110452?lang=zh_cn&edition=full","pubTime":"2023-12-21 06:08","pubTimestamp":1703110113,"startTime":"0","endTime":"0","summary":"Svea Herbst-Bayliss    路透纽约12月20日 - 生物技术公司BioMarin   与激进投资者埃利奥特投资管理公司达成和解，该公司将在董事会中增加三名独立董事，并成立一个委员会来审查公司的运营情况。该协议标志着掌管 600 亿美元资产的 Elliott 本周达成的第二项和解协议。在 BioMarin，公司和对冲基金就三位与 Elliott 没有直接关系的行业和金融专家达成了一致。该公司表示，BioMarin 董事会将暂时扩大到 15 名董事，明年股东大会后将恢复到 11 名董事。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2391667187","title":"血友病领域评估各种选择方案时，新的血友病基因疗法接受速度缓慢","url":"https://stock-news.laohu8.com/highlight/detail?id=2391667187","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2391667187?lang=zh_cn&edition=full","pubTime":"2023-12-15 20:00","pubTimestamp":1702641604,"startTime":"0","endTime":"0","summary":"血友病患者体内有一种调节凝血因子蛋白质生产的基因存在缺陷。一年多前，美国监管机构批准了第一种一次性治疗 B 型血友病的基因疗法，即 CSL 的   Hemgenix。目前，使用最广泛的A型血友病治疗药物是罗氏公司的  抗体Hemlibra，该药物于2017年获得美国批准。与只批准成人使用的基因疗法不同，Hemlibra可用于所有年龄段，包括婴儿。辉瑞和罗氏也在开发血友病基因疗法。","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":-0.0004},{"period":"1month","weight":-0.0558},{"period":"3month","weight":-0.0857},{"period":"6month","weight":-0.0399},{"period":"1year","weight":-0.1504},{"period":"ytd","weight":-0.1485}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":-0.0036},{"period":"3month","weight":0.0457},{"period":"6month","weight":0.1814},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.0868}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.位于特拉华州，研发生产创新生物技术药物，治疗严重的疾病和健康问题。拜玛琳公司选择候选产品时，选择还未解决的具有重大意义的疾病和问题，对生物学有充分的认识，有机会率先面市或者使现有产品得到重大改进。公司产品组合包括四项定型产品和多项临床试验的候选产品。公司的定型产品分别是Naglazyme（加硫酶），Kuvan（二盐酸沙丙蝶呤），Firdapse（药磷酸阿米吡啶）和Aldurazyme（拉罗尼酶）。公司于1996年在特拉华州注册，于1997年3月21号运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.68,"avgChangeRate":0.053118},{"month":2,"riseRate":0.44,"avgChangeRate":0.00883},{"month":3,"riseRate":0.48,"avgChangeRate":0.00524},{"month":4,"riseRate":0.52,"avgChangeRate":-0.015671},{"month":5,"riseRate":0.56,"avgChangeRate":0.013443},{"month":6,"riseRate":0.625,"avgChangeRate":0.016585},{"month":7,"riseRate":0.625,"avgChangeRate":0.039624},{"month":8,"riseRate":0.52,"avgChangeRate":-0.001402},{"month":9,"riseRate":0.48,"avgChangeRate":-0.001794},{"month":10,"riseRate":0.44,"avgChangeRate":-0.025565},{"month":11,"riseRate":0.8,"avgChangeRate":0.064297},{"month":12,"riseRate":0.64,"avgChangeRate":0.034986}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}